Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

NCT05240131 is registered in ClinicalTrials.gov with Galecto Biotech AB as lead sponsor.

NCT NCT05240131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05240131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Lead sponsor
Galecto Biotech AB
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 15, 2022
Completion date
November 1, 2025
Enrollment
88 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer